Liu Y - Search Results

1

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X. Xu J, et al. Among authors: liu y, liu s. Nat Nanotechnol. 2019 May;14(5):496. doi: 10.1038/s41565-019-0417-y. Nat Nanotechnol. 2019. PMID: 30837690

2

Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X. Xu J, et al. Among authors: liu y, liu s. Nat Nanotechnol. 2019 Apr;14(4):388-397. doi: 10.1038/s41565-019-0381-6. Epub 2019 Feb 25. Nat Nanotechnol. 2019. PMID: 30804480 Free PMC article.

3

Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X. Xu J, et al. Among authors: liu y, liu s. Nat Nanotechnol. 2020 Apr;15(4):342. doi: 10.1038/s41565-020-0635-3. Nat Nanotechnol. 2020. PMID: 31953520

4

Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Liu Y, Xu H, Van der Jeught K, Li Y, Liu S, Zhang L, Fang Y, Zhang X, Radovich M, Schneider BP, He X, Huang C, Zhang C, Wan J, Ji G, Lu X. Liu Y, et al. Among authors: liu s. J Clin Invest. 2018 Jul 2;128(7):2951-2965. doi: 10.1172/JCI98727. Epub 2018 Jun 4. J Clin Invest. 2018. PMID: 29649003 Free PMC article.

5

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, Fang Y, Zhou Z, Zhang L, Frieden M, Wang L, Luo Z, Radovich M, Schneider BP, Deng Y, Liu Y, Huang K, He B, Wang J, He X, Zhang X, Ji G, Lu X. Li Y, et al. Among authors: liu y. Nat Commun. 2018 Oct 22;9(1):4394. doi: 10.1038/s41467-018-06811-z. Nat Commun. 2018. PMID: 30349055 Free PMC article.

6

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X, He X, Zhang X. Liu Y, et al. Among authors: liu s. Nat Commun. 2018 Nov 9;9(1):4718. doi: 10.1038/s41467-018-07264-0. Nat Commun. 2018. PMID: 30413718 Free PMC article.

7

Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of TP53 Deficiency in Colon and Rectal Cancers.

Xu J, Liu Y, Liu S, Ou W, White A, Stewart S, Tkaczuk KHR, Ellis LM, Wan J, Lu X, He X. Xu J, et al. Among authors: liu y, liu s. Nano Today. 2022 Apr;43:101406. doi: 10.1016/j.nantod.2022.101406. Epub 2022 Feb 1. Nano Today. 2022. PMID: 35251293 Free PMC article.

8

Non-coding RNAs in DNA damage response.

Liu Y, Lu X. Liu Y, et al. Am J Cancer Res. 2012;2(6):658-75. Epub 2012 Nov 20. Am J Cancer Res. 2012. PMID: 23226613 Free PMC article.

9

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. Liu Y, et al. Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22. Nature. 2015. PMID: 25901683 Free PMC article.

10

Targeting tumor suppressor genes for cancer therapy.

Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X. Liu Y, et al. Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7. Bioessays. 2015. PMID: 26445307 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,465 results

Search Page

Filters